Cover Image

Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer

PURPOSEIn KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective of tumor p...

Full description

Saved in:
Bibliographic Details
Main Authors: Gadgeel, Shirish (Author) , Rodríguez-Abreu, Delvys (Author) , Speranza, Giovanna (Author) , Esteban, Emilio (Author) , Felip, Enriqueta (Author) , Dómine, Manuel (Author) , Hui, Rina (Author) , Hochmair, Maximilian J. (Author) , Clingan, Philip (Author) , Powell, Steven F. (Author) , Cheng, Susanna Yee-Shan (Author) , Bischoff, Helge (Author) , Peled, Nir (Author) , Grossi, Francesco (Author) , Jennens, Ross R. (Author) , Reck, Martin (Author) , Garon, Edward B. (Author) , Novello, Silvia (Author) , Rubio-Viqueira, Belén (Author) , Boyer, Michael (Author) , Kurata, Takayasu (Author) , Gray, Jhanelle E. (Author) , Yang, Jing (Author) , Bas, Tuba (Author) , Pietanza, M. Catherine (Author) , Garassino, Marina C. (Author)
Format: Article (Journal)
Language:English
Published: March 9, 2020
In: Journal of clinical oncology
Year: 2020, Volume: 38, Issue: 14, Pages: 1505-1517
ISSN:1527-7755
DOI:10.1200/JCO.19.03136
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.19.03136
Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.19.03136
Get full text
Author Notes:Shirish Gadgeel, MB, BS; Delvys Rodríguez-Abreu, MD; Giovanna Speranza, MD, MSc; Emilio Esteban, MD; Enriqueta Felip, MD, PhD; Manuel Dómine, MD, PhD; Rina Hui, MB, BS, PhD; Maximilian J. Hochmair, MD; Philip Clingan, MB, BS; Steven F. Powell, MD; Susanna Yee-Shan Cheng, MD; Helge G. Bischoff, MD; Nir Peled, MD, PhD; Francesco Grossi, MD; Ross R. Jennens, MB, BS; Martin Reck, MD; Edward B. Garon, MD; Silvia Novello, MD, PhD; Belén Rubio-Viqueira, MD; Michael Boyer, MB, BS, PhD; Takayasu Kurata, MD, PhD; Jhanelle E. Gray, MD; Jing Yang, PhD; Tuba Bas, PhD; M. Catherine Pietanza, MD; and Marina C. Garassino, MD
Description
Summary:PURPOSEIn KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 (PD-L1) expression. We report an updated analysis from KEYNOTE-189 (ClinicalTrials.gov: NCT02578680).METHODSPatients were randomly assigned (2:1) to receive pemetrexed and platinum plus pembrolizumab (n = 410) or placebo (n = 206) every 3 weeks for 4 cycles, then pemetrexed maintenance plus pembrolizumab or placebo for up to a total of 35 cycles. Eligible patients with disease progression in the placebo-combination group could cross over to pembrolizumab monotherapy. Response was assessed per RECIST (version 1.1) by central review. No alpha was assigned to this updated analysis.RESULTSAs of September 21, 2018 (median follow-up, 23.1 months), the updated median (95% CI) OS was 22.0 (19.5 to 25.2) months in the pembrolizumab-combination group versus 10.7 (8.7 to 13.6) months in the placebo-combination group (hazard ratio [HR], 0.56; 95% CI, 0.45 to 0.70]). Median (95% CI) PFS was 9.0 (8.1 to 9.9) months and 4.9 (4.7 to 5.5) months, respectively (HR, 0.48; 95% CI, 0.40 to 0.58). Median (95% CI) time from randomization to objective tumor progression on next-line treatment or death from any cause, whichever occurred first (progression-free-survival-2; PFS-2) was 17.0 (15.1 to 19.4) months and 9.0 (7.6 to 10.4) months, respectively (HR, 0.49; 95% CI, 0.40 to 0.59). OS and PFS benefits with pembrolizumab were observed regardless of PD-L1 expression or presence of liver/brain metastases. Incidence of grade 3-5 adverse events was similar in the pembrolizumab-combination (71.9%) and placebo-combination (66.8%) groups.CONCLUSIONFirst-line pembrolizumab plus pemetrexed-platinum continued to demonstrate substantially improved OS and PFS in metastatic nonsquamous NSCLC, regardless of PD-L1 expression or liver/brain metastases, with manageable safety and tolerability.
Item Description:Gesehen am 06.05.2021
Physical Description:Online Resource
ISSN:1527-7755
DOI:10.1200/JCO.19.03136

Similar Items